NCT03636750View on ClinicalTrials.gov

A Study of Injection HB002.1T in Subjects With Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 28, 2018

Primary Completion Date

February 20, 2020

Study Completion Date

March 21, 2020

Conditions
Solid Tumor
Interventions
DRUG

HB002.1T

HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy

Trial Locations (1)

200123

Shanghai East Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Huabo Biopharm Co., Ltd.

INDUSTRY